RxDoctor Payments Data

Arnold Brizuela, MD

Neurology · Arcadia, CANPI 1528325818

Payments from drug & device makers

$38,363in general payments, 2019–2025

Across 1,918 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$5K
  • Biogen$3K
  • AbbVie$3K
  • AstraZeneca$2K
  • Novartis$2K
  • Lilly USA, LLC$2K
  • plus $21K from 54 others

What the payments were for

  • Speaking & faculty fees$400%
  • Travel & lodging$60%
  • Food & beverage$37,76698%
  • Education$5521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.229$4,907
Biogen112$2,713
AbbVie(2 entities)152$2,646
AstraZeneca(2 entities)82$2,182
Novartis121$2,099
Lilly USA, LLC97$1,801
Neurocrine Biosciences, Inc.65$1,564
Lundbeck LLC85$1,518
Pfizer73$1,444
Acadia Pharmaceuticals Inc59$1,195
Amgen(2 entities)51$1,119
Teva Pharmaceuticals USA, Inc.45$1,089
Eisai Inc.41$1,039
Amneal Pharmaceuticals LLC50$933
Supernus Pharmaceuticals, Inc.77$744
MDD US Operations, LLC45$715
EMD Serono, Inc.30$679
Sanofi24$529
Argenx US, Inc.25$517
Jazz Pharmaceuticals Inc.19$510
SK Life Science, Inc.32$507
Otsuka America Pharmaceutical, Inc.22$496
Biohaven Pharmaceutical Holding Company Ltd.28$439
Biohaven Pharmaceuticals, Inc.22$356
Johnson & Johnson(2 entities)10$311
Alnylam Pharmaceuticals Inc.15$298
Zyla Life Sciences, Inc.35$273
Grifols USA, LLC10$256
Bristol Myers Squibb14$246
Ipsen Biopharmaceuticals, Inc9$238
Octapharma USA, Inc.9$224
Takeda Pharmaceuticals U.S.A., Inc.10$210
Aquestive Therapeutics, Inc.12$209
Almatica Pharma LLC14$207
Corium, LLC10$200
Abbott6$197
TG Therapeutics, Inc.7$195
Neurelis, Inc.8$194
Greenwich Biosciences, Inc.7$170
Mallinckrodt Hospital Products Inc.5$154
ANI Pharmaceuticals, Inc.6$145
Axsome Therapeutics, Inc.7$144
Merz Pharmaceuticals, LLC5$144
Kyowa Kirin, Inc.8$142
Arbor Pharmaceuticals, Inc.8$136
Acorda Therapeutics, Inc6$136
Avanir Pharmaceuticals, Inc.6$135
Sunovion Pharmaceuticals Inc.7$132
CSL Behring7$124
Genentech USA, Inc.4$117
Zogenix Inc.5$112
Boston Scientific4$110
Adamas Pharmaceuticals, Inc.5$107
Catalyst Pharmaceuticals, Inc.5$94
Harmony Biosciences LLC3$85
Cycle Pharmaceuticals Inc3$81
Assertio Therapeutics, Inc.5$79
Avadel CNS Pharmaceuticals, LLC3$79
Azurity Pharmaceuticals, Inc.5$78
Neuropace, Inc.3$64

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,363 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$190,821
Medicare patients
265
Services billed
8,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate40$259,058
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5031$252,031
GocovriAmantadine Hcl53$228,058
RytaryCarbidopa/Levodopa125$152,290
RexultiBrexpiprazole73$118,908
ZeposiaOzanimod Hydrochloride13$117,879
IngrezzaValbenazine Tosylate12$111,906
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5017$109,830
BotoxOnabotulinumtoxina89$107,562
Emgality PenGalcanezumab-Gnlm124$90,426
Nurtec OdtRimegepant Sulfate39$52,649
BriviactBrivaracetam24$50,687
QuliptaAtogepant12$30,260
Aimovig AutoinjectorErenumab-Aooe37$27,212
UbrelvyUbrogepant25$26,988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,195$259,05840 claims
MDD US Operations, LLCGocovri$715$228,05853 claims
AbbVieBotox, Qulipta, Ubrelvy$2,646$164,809126 claims
Amneal Pharmaceuticals LLCRytary$933$152,290125 claims
Otsuka America Pharmaceutical, Inc.Rexulti$496$118,90873 claims
Neurocrine Biosciences, Inc.Ingrezza$1,564$111,90612 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$210$109,83017 claims
PfizerNurtec Odt$1,444$52,64939 claims
UCB, Inc.Briviact$4,907$50,68724 claims
Arbor Pharmaceuticals, Inc.Horizant$136$14,31811 claims
Corium, LLCAdlarity$200$10,40424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →